Introduction {#s0005}
============

This executive summary briefly describes the overall goals and content of the report on safety considerations for intensity modulated radiation therapy (IMRT) and is intentionally limited in length and content. Please see the full report published electronically at [www.practicalradonc.org](http://www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext). This abridged version is not intended to replace the full length report but rather to highlight key recommendations of the report. Background information for those less familiar with IMRT is limited to the full report.

Scope of this document on patient safety for IMRT {#s0010}
-------------------------------------------------

This report is part of a series of white papers addressing patient safety commissioned by the American Society for Radiation Oncology (ASTRO) Board of Directors as part of ASTRO\'s Target Safely Campaign. The full length document was approved by the ASTRO Board of Directors on February 14, 2011 and has been endorsed by the American Association of Physicists in Medicine, American Association of Medical Dosimetrists, and the American Society of Radiologic Technologists. The document has also been reviewed and accepted by the American College of Radiology's Commission on Radiation Oncology. These organizations have a long history of supporting efforts toward improving patient safety in the United States.

This report is related to other reports of the ASTRO white paper series on patient safety, still in preparation, especially those on peer review and on image-guided radiation therapy, since both of these areas have implications on the practice of IMRT. There are sections of the report that defer to guidance that will be published by those groups in future reports. Because this is the first report in the safety series, some of the concerns included in this report are not limited to IMRT.

IMRT provides increased capability to conform isodose distributions to the shape of the target(s), thereby reducing dose to some adjacent critical structures. This promise of IMRT is one of the reasons for its widespread use. However, the promise of IMRT is counterbalanced by the complexity of the IMRT planning and delivery processes, and the associated risks.

The *New York Times* reported on serious accidents involving both IMRT and other radiation treatment modalities.[@bb0005; @bb0010] The full length report broadly addresses safe delivery of IMRT, with a primary focus on recommendations for human error prevention and methods to reduce the occurrence of errors or machine malfunctions that can lead to *catastrophic failures or errors.*

The full treatment team should be composed of individuals with proper credentials and training specific to radiation therapy for the simulation, treatment planning, quality assurance (QA), and delivery processes. Additional training specific to IMRT is important. See the full length report (section 1.2, available online only at [www.practicalradonc.org](http://www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext)) for a description of the responsibilities of IMRT team members, including radiation oncologists, medical physicists, dosimetrists (or treatment planners), radiation therapists, and administrative staff. Special attention should be paid to the roles of the physician and physicist; both board certified medical specialists who share responsibility for IMRT quality.

Safety concerns {#s0015}
===============

Tools and techniques that can be used by individual clinics to reassess and strengthen the safety of their IMRT programs are presented in the full length document. Due to the complexity of IMRT delivery, we believe it is unsafe for IMRT to be delivered in emergent situations that would encourage staff to skip the needed QA steps. And yet, clinical pressures can make it difficult to ensure support for this approach.

Hazards within an IMRT program can be broadly categorized as environmental or technical. Environmental concerns that can affect all patient treatments include the lack of standard operating procedures, haste, habituation, incomplete understanding or misuse of procedures or equipment, an inadequate QA program, and a lack of continuing staff education. While these hazards are not unique to IMRT, their impact may be greater due to the complexity of IMRT. Technical concerns that affect safety can include inadequate commissioning of the clinical IMRT program, inadequate validation of the accuracy of treatment delivery parameters, improper use of one or more parts of the planning and delivery process, and an inadequate investigation of discrepancies between treatment plan parameters and QA results.

The responsibilities of members of the treatment team are defined in the report (see [Table 2](#app0005){ref-type="sec"} in the full document; available online only at [www.practicalradonc.org](http://www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext)). Also, specific example process steps are presented for workflow ([Appendix 1](#app0005){ref-type="sec"} in full document; available online only at [www.practicalradonc.org](http://www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext)) and checklists ([Appendix 2](#app0005){ref-type="sec"}; available online only at [www.practicalradonc.org](http://www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext)), which may address ways to prevent or detect catastrophic failures for IMRT. The 54 process steps and 15 hand-offs between the personnel in the example workflow illustrate the critical need for clearly defined roles, and unambiguous or robust hand-offs (and means of communication) between personnel.

Supporting a culture of safety for IMRT: environmental considerations {#s0020}
=====================================================================

The departmental leadership establishes the foundation for patient safety and teamwork. While these elements are not unique to IMRT, we believe that they are crucial for ensuring a safe radiation therapy program, especially since IMRT requires additional equipment, personnel, and procedures for safety. The following considerations (discussed in detail in the full length document available online only at [www.practicalradonc.org](http://www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext)) are important for creation of a culture of safety:•Department members must trust each other[@bb0015]•Administration must provide strong support for safety•Event tracking, review, investigation, and follow-up for events and near misses•Appropriately qualified personnel and ongoing training•Use of standard operating procedures (SOPs)•Defined roles and responsibilities for team members•Strong communication among team members•American College of Radiology /ASTRO practice accreditation•Continuous quality improvements.

Each institution should customize procedures to reflect their own processes and resources but should have a basis founded in national or international guidance documents (section 4) to create a program that explicitly incorporates patient safety. SOPs should be written and should empower individuals to halt planning or treatment when a problem is encountered, allowing for proper investigation into the problem, and then a decision regarding the best course of action to maintain patient safety. In the midst of a situation where adequate time is *not* allowed for performing all of the necessary QA steps prior to treatment, time pressures may stand in the way of identifying and resolving problems. The SOP should not permit staff to skip QA steps.

Implementation of and adherence to detailed policies and procedures are necessary to avoid both quality errors and catastrophic failures. Details of what should be included in an IMRT SOP are in the full length document (available online only at [www.practicalradonc.org](http://www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext)).

[Figure 1](#f0005){ref-type="fig"} shows the complexity of the IMRT process as a series of process steps and review steps by members of the IMRT team. There are numerous situations (eg, a change in the patient geometry) that can lead to restarting the process from the beginning, which can cause pressures to skip or short-circuit QA procedures. Risks may also increase if inadequate time is allotted for, and in between, the various steps (eg, image segmentation, written directive, planning, patient-specific QA). The full length report discusses many of these time considerations (with respect to safety) in detail.

IMRT guidance for quality assurance experience: technical considerations {#s0025}
========================================================================

A summary of the existing guidance documents for IMRT is presented in the full length document (text and [Table 5](#app0005){ref-type="sec"} available online only at [www.practicalradonc.org](http://www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext)). These earlier IMRT QA documents emphasized establishing a quality IMRT program and did not explicitly concentrate on the potential for catastrophic failures in IMRT delivery. In fact, several documents suggested that some QA efforts could be decreased or even eliminated after the accumulation of a stated amount of experience. *In this work, we acknowledge that certain types of catastrophic failures resulting from human error and equipment (hardware or software) malfunction might not be predictable based on past experience. In some situations, periodic testing alone may be inadequate for identifying these types of problems.*

The processes and tasks performed by the IMRT team are addressed with special attention to patient safety and to minimizing the potential for *catastrophic failures*. The full length document (available online only at [www.practicalradonc.org](http://www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext)) includes a detailed discussion of the following with respect to patient safety and quality:4.2.1 Training4.2.2 Commissioning an IMRT system4.2.3 Establishing a QA program4.2.4 Pretreatment IMRT QA program4.2.5 Monitoring the IMRT program

Each institution should have clear criteria for a pass or fail of the IMRT patient-specific IMRT QA technique. There is interinstitutional variation in the *content* of pretreatment IMRT QA, as well as the equipment and software used. There is no formal consensus on the desired or required level of agreement between the planned or expected calculation and the measured data for patient-specific IMRT QA. Also, the impact of failing to meet a given set of criteria on these patient-specific measurements is often not explicitly addressed (eg, remeasure the fields, generate an alternate plan, estimate the clinical impact qualitatively, etc). Therefore, further guidance is needed from national organizations in each of these areas.

Until formal guidance is available, we recommend that users establish acceptance criteria that they have determined will identify plans that should fail the QA check. For example, users should deliberately create plans with known errors such as the incorrect fluence for regions of high or low dose across the irradiated volume or critical structures, plans with one field with a rotated collimator and/or an incorrect fluence distribution, and other discrepancies that should be identified by the QA method. The IMRT QA criteria should be established using tests of the most highly modulated fields that are seen in the local clinic.

The full length report includes a summary of the primary recommendations, tasks, and assigned personnel to guard against catastrophic failures for IMRT, primarily concentrating on multileaf collimator-based delivery systems since they are the most common ([Table 4](#t0005){ref-type="table"}).

Collaboration between users and manufacturers to improve IMRT safety {#s0030}
====================================================================

Improvements in IMRT equipment and methods to enhance patient safety are needed and would be facilitated by collaborative efforts between manufacturers, users, and regulatory agencies such as the United States Food and Drug Administration. The full length report includes a detailed list of possible improvements, including the following:A.Methods to directly and independently verify or validate patient plan and treatment data on the treatment machine prior to, during, and after radiation delivery.B.Provision of safety measures in the IMRT workflow such as communication features, checklists, data integration and tracking.C.Integration of IMRT sub-systems and QA proceduresD.Human interaction with equipment

Successful improvements to existing and future systems will require joint efforts by the users, vendors, and regulators. The prioritization, implementation, testing, and commercial release of any improvements should be a partnership between users, manufacturers, and regulators.

Summary {#s0035}
=======

IMRT is time and resource intensive. Environmental and technical concerns need to be addressed to improve patient safety. Timely treatment is important, but undue pressure and real-time changes to the treatment plan can lead to errors. The report suggests use of a "forced time out" to assure adequate time to perform reviews and QA at key points in the process. Team members need to acknowledge that initiation of treatment may need to be delayed to allow time for necessary QA checks and subsequent investigations of problems.

The recommendations in the full length report are intended to provide guidance to aid clinics in avoiding catastrophic errors and to improve the safety and quality of care for patients receiving IMRT. It is expected that there will be further developments with respect to the evaluation of IMRT programs for accreditation, and that new guidance documents will continue to enhance the quality and safety of IMRT use.

 {#app0005}
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![An abbreviated diagram of the process (boxes) and review (ovals) steps for intensity modulated radiation therapy planning for an individual patient. Each color (or shade) represents member of the treatment team. \*Peer review will be addressed in detail in a report of the white paper series on patient safety.](gr1){#f0005}

###### 

Recommendations to guard against catastrophic failures for IMRT

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Recommended tests and procedures                                                                                                                                                                              Person who performs task                                              Primary review responsibility   Second review
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  Halt a procedure if the operator is unclear about what is being done.                                                                                                                                         All                                                                   All                             All

                                                                                                                                                                                                                                                                                                                      

  Verify the patient information, treatment site, and prescription.                                                                                                                                             All                                                                   All                             All

                                                                                                                                                                                                                                                                                                                      

  Verify correct positioning of the high dose region of isodose plan relative to targets.                                                                                                                       Dosimetrist                                                           Physician                       Physicist

                                                                                                                                                                                                                                                                                                                      

  Verify the recording of reference and shift information from the planning scan in patient chart (electronic or paper).                                                                                        Dosimetrist                                                           Physicist                       Therapist

                                                                                                                                                                                                                                                                                                                      

  Assess pretreatment localization/portal images with respect to corresponding reference images before first treatment; physician determines frequency of IGRT techniques.                                      Dosimetrist exports reference images from treatment planning system   Physician                       Therapist

                                                                                                                                                                                                                                                                                                                      

  Verify that the correct version of the patient\'s treatment plan is approved, sent to treatment management system, and used for patient-specific QA.                                                          Dosimetrist exports from the treatment planning system                Physicist                       Therapists confirm against prescription for each treatment; physician prescription should specify the physician approved plan

                                                                                                                                                                                                                                                                                                                      

  Before the first treatment or for any change in treatment, perform patient-specific QA to guarantee that data transfer between systems is correct before patient treatment begins.                            Physicist, dosimetrist, therapist or physics assistant                Physicist                       Therapists confirm that only fully approved plans are used for treatment

                                                                                                                                                                                                                                                                                                                      

  Perform a complete chart check including review of information in treatment management system prior to the start of any treatment and after any change in treatment before changes are used for treatment.\   Physicist                                                             Therapist                       
  Visually review field apertures in treatment management system.\                                                                                                                                                                                                                                                    
  Perform a check of dose to verify TPS calculation (measurement or calculation using DICOM export of data from RTP system).                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                      

  Perform a time out prior to treatment delivery.                                                                                                                                                               Therapist                                                             Second therapist                

                                                                                                                                                                                                                                                                                                                      

  Perform a check of treatment parameters before start of and during first treatment against a fixed version of the treatment plan.\                                                                            Dosimetrist exported from TPS; verified by physicist                  Therapist                       Second therapist
  Includes visual verification of field apertures during first treatment and after any change in treatment.\                                                                                                                                                                                                          
  At each fraction, verify motion of leaves (if MLC delivery) and total monitor units.                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                      

  Perform end-to-end testing to guarantee transfer of data among all systems involved in imaging, planning and dose delivery (periodically and after any software or hardware changes).                         Physicist, therapist, or physics assistant                            Physicist                       Second physicist to review

                                                                                                                                                                                                                                                                                                                      

  Perform a time out prior to treatment delivery.                                                                                                                                                               Therapist                                                             Second therapist                

                                                                                                                                                                                                                                                                                                                      

  Perform a check of treatment parameters before start of and during first treatment against a fixed version of the treatment plan.\                                                                            Dosimetrist exported from TPS; verified by physicist                  Therapist                       Second therapist
  Includes visual verification of field apertures during first treatment and after any change in treatment.\                                                                                                                                                                                                          
  At each fraction, verify motion of leaves (if MLC delivery) and total monitor units.                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                      

  Perform end-to-end testing to guarantee transfer of data among all systems involved in imaging, planning and dose delivery (periodically and after any software or hardware changes).                         Physicist, therapist, or physics assistant                            Physicist                       Second physicist to review
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IGRT, image-guided radiation therapy; IMRT, intensity modulated radiation therapy; MLC, multileaf collimator; QA, quality assurance; TPS, treatment planning system.
